Special Issues and Supplements

2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma
First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma
Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes
Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Multiple Myeloma
2021 Year in Review - Multiple Myeloma
First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma
First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma
February 2022 Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice
2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments
2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments
2021 Year in Review - HER2-Negative Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Renal-Cell Carcinoma
Reducing Racial Disparities in Cancer Care Using the ACCURE Trial as a Model Learning Guide
Reducing Racial Disparities in Cancer Care Using the ACCURE Trial as a Model Learning Guide
2021 Year in Review - Biosimilars
2021 Year in Review - Biosimilars
2021 Year in Review: Non–Small-Cell Lung Cancer
2021 Year in Review: Non–Small-Cell Lung Cancer
MOA Magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)
MOA Magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)
Interview with the Innovators – December 2021
Interview with the Innovators – December 2021
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Triple-Negative Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
2021 Midyear Review: Non–Small-Cell Lung Cancer
2021 Midyear Review: Non–Small-Cell Lung Cancer
Best Practices in Genitourinary Oncology Navigation: Renal-Cell Carcinoma – July 2021
Best Practices in Genitourinary Oncology Navigation: Renal-Cell Carcinoma – July 2021
March 2021 Clinical Trials to Clinical Practice
March 2021 Clinical Trials to Clinical Practice
2020 Year in Review: Non–Small-Cell Lung Cancer
2020 Year in Review: Non–Small-Cell Lung Cancer
AONN+ 2020 Conference Highlights Special Feature
AONN+ 2020 Conference Highlights Special Feature
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review - Ovarian Cancer
2020 Year in Review - Ovarian Cancer
2020 Year in Review - Neuroendocrine Tumors
2020 Year in Review - Neuroendocrine Tumors
2020 Year in Review - Breast Cancer
2020 Year in Review - Breast Cancer
2020 Year in Review - Biosimilars
2020 Year in Review - Biosimilars
2020 Year in Review - Multiple Myeloma
2020 Year in Review - Multiple Myeloma
Faculty Perspectives: Current Guidelines and Emerging Treatments in Nonmetastatic NSCLC
Faculty Perspectives: Current Guidelines and Emerging Treatments in Nonmetastatic NSCLC
June 2020 Clinical Trials to Clinical Practice
June 2020 Clinical Trials to Clinical Practice
  • 1
  • 2
Page 1 of 2
Results 1 - 30 of 59

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2021 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512